Panel slams Alzheimer’s drug.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      UNITED States. Food & Drug Administration
    • Abstract:
      The article reports that Aducanumab, an antibody drug for Alzheimer developed by Biogen, has been disapproved by an independent advisory panel and informs that the U.S. Food & Drug Administration (FDA) was expected to decide about the drug by March 2021.